Molecular Pathology and Tissue Resource
Molecular Pathology and Tissue Resource
批准号:
10203840
负责人:
Justin A. Bishop
金额:
$18.94万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
未结题
起止时间:
1997-09-05 至 2025-08-31
关键词:
B-LymphocytesBasic ScienceBeliefBloodBlood CellsBlood specimenCancer PatientCancer cell lineCatalogsCell LineCellsClinicalClinical DataClinical ResearchClinical TrialsCollaborationsCollectionConfidentiality of Patient InformationConsentDNADataData AnalysesData Science CoreDepositionDevelopmentDrug or chemical Tissue DistributionEnsureEpithelial CellsExtramural ActivitiesFosteringFundingGenomicsGoalsGrantGuidelinesHistologicHumanImmuneImmunogenomicsImmunotherapyInformed ConsentInstitutionInstitutional Review BoardsInvestigationLungLung NeoplasmsMalignant - descriptorMalignant neoplasm of lungMeasuresMethodologyMethodsMolecularMolecular AnalysisNeoadjuvant StudyNeoplasm Circulating CellsNon-MalignantNon-Small-Cell Lung CarcinomaOperative Surgical ProceduresPathogenesisPathologicPathologyPatient-Focused OutcomesPatientsPeer ReviewPlayPositioning AttributeProcessProteinsProtocols documentationPublicationsRNAReagentResearchResearch ActivityResearch PersonnelResearch Project GrantsResectableResource SharingResourcesRoleSamplingServicesSiteSpecimenTestingTissue MicroarrayTissue ProcurementsTissue SampleTissuesTranslational ResearchTumor Cell LineUnited States National Institutes of HealthUniversity of Texas M D Anderson Cancer CenterXenograft procedurebasecareerclinical translationdata sharinghigh standardimmune checkpoint blockadeimmunopathologyindividual patientinnovationliquid biopsylung cancer celllung small cell carcinomamolecular pathologynovelpersonalized medicineprogramsrepositorysuccesssynergismtissue resourcetranslational cancer researchtumortumor xenografttumor-immune system interactions
中文摘要
病理学核心(核心B)项目总结/摘要
分子病理学和组织资源核心将提供常规和创新的组织资源,
实现SPORE项目目标所必需的材料。常规材料包括肿瘤、非-
恶性肺标本、肿瘤细胞系和临床注释,所有这些都是在知情的情况下获得的。
同意和确保患者保密的措施。超过6,000种肿瘤,包括临床上
注释的组织微阵列(TMAs),300种所有组织学类型的肺癌细胞系,以及超过180种肺肿瘤
患者来源的和循环肿瘤细胞来源的异种移植物(PDX/CDX)可供研究者使用。许多
这些样本已分发给我们的SPORE调查人员,以及我们自己的其他调查人员。
和外部机构(包括其他SPORE)。这些伙伴关系助长了多种肺癌
转化研究合作,并在过去十年中发表了380多篇出版物。此外
重要的临床和组织学注释,基因组,分子和免疫微环境分析
这些样本中的50%为相关数据和协同作用提供了重要的人体终点,
孢子和其他肺癌转化研究的组成部分。鉴于日益重要的
肺癌的免疫治疗,病理学核心已经开发出方法,提供最先进的免疫
分析注释。此外,核心还参与了从MDACC收集患者样本的工作
非小细胞肺癌(ICON)的免疫基因组学分析和NEO佐剂诱导检查点阻断的研究
可切除的I-IIIA期NSCLC(NEOSTAR)临床试验。我们的目标1是收集,处理,存储,目录和
分发恶性和非恶性的组织、细胞系和血液样本、肿瘤异种移植物,以及
相关的临床病理学和分子数据,根据SPORE的各个组成项目的要求
项目;我们将使用IRB批准的方案、知情同意书和保护受试者机密性的措施。
目标2是开发和利用创新和常规的组织和细胞系资源,这将有助于成功地
完成SPORE计划的目标;这些目标包括开发新的肿瘤细胞系,额外的肺
肿瘤TMA资源,肿瘤和液体活检的分子分析,
组织中目标3是执行、解释、分析和存款基于组织的分子和免疫分析
与组件项目、DRP、CEP和数据科学核心密切合作,
SPORE计划,以实现其批准的目标。在这些目标中,病理学核心将发挥关键作用,
在促进我们自己的SPORE调查人员之间的纵向和横向合作方面,
肺癌孢子网站,以及我们自己和其他机构的其他研究人员。我们所有的SPORE项目
将使用核心B材料和服务。大量使用我们的常规和创新材料,以及
与SPORE调查人员的互动,将极大地帮助我们成功完成SPORE的目标
提议
英文摘要
Pathology Core (Core B) Project Summary/Abstract
The Molecular Pathology and Tissue Resources Core will provide routine and innovative tissue resources and
materials essential for achieving the aims of the SPORE projects. Routine materials include tumors, non-
malignant lung specimens, tumor cell lines, and clinical annotation, all of which have been obtained with informed
consent and measures to ensure patient confidentiality. Over 6,000 tumors including tumors on clinically
annotated tissue microarrays (TMAs), 300 lung cancer cell lines of all histologic types, and over 180 lung tumor
patient-derived and circulating tumor cell-derived xenografts (PDXs/CDXs) are available to investigators. Many
of these samples have been distributed to our SPORE investigators, as well as other investigators at our own
and outside institutions (including other SPOREs). These partnerships have fueled multiple lung cancer
translational research collaborations, and have generated over 380 publications in the last ten years. In addition
to important clinical and histologic annotation, the genomic, molecular, and immune microenvironment profiling
of these samples provide important Human Endpoints for correlative data and synergy, both within the UT Lung
SPORE and as components of other lung cancer translational research. Given the increasing importance of
immunotherapy for lung cancer, the Pathology Core has developed methods to provide state of the art immune
profiling annotation. Additionally, the Core has participated in collection of patient samples from the MDACC
ImmunogenomiC prOfiling of NSCLC (ICON) and NEOadjuvant STudy of induction checkpoint blockade for
Resectable stage I-IIIA NSCLC (NEOSTAR) clinical trials. Our Aim 1 is to collect, process, store, catalog and
distribute tissues, cell lines and blood specimens, both malignant and non- malignant, tumor xenografts, and
relevant clinico-pathologic and molecular data, as requested by the various component projects of the SPORE
program; we will use IRB-approved protocols, informed consent, and measures to protect subject confidentiality.
Aim 2 is to develop and utilize innovative and routine tissue and cell line resources that will aid in the successful
completion of the SPORE program aims; these include development of new tumor cell lines, additional lung
cancer TMA resources, molecular analysis of tumors and liquid biopsy, and comprehensive immune profiling of
tissues. Aim 3 is to perform, interpret, analyze, and deposit tissue-based molecular and immune analysis
methodologies in close collaboration with the component Projects, DRP, CEP, and Data Sciences Core of the
SPORE program to achieve their approved aims. Within these aims, the Pathology Core will play a crucial role
in promoting vertical and horizontal collaborations among our own SPORE investigators, investigators at other
Lung Cancer SPORE sites, and other investigators at our own and other institutions. All of our SPORE projects
will use Core B materials and services. Heavy utilization of our routine and innovative materials, as well as close
interactions with the SPORE investigators, will greatly aid the successful completion of the aims of our SPORE
proposal.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular Pathology and Tissue Resource
-
批准号:10701012
-
项目类别:
-
资助金额:$20.04万
-
财政年份:1997
-
负责人:Justin A. Bishop
-
依托单位:
Molecular Pathology and Tissue Resource
-
批准号:10023863
-
项目类别:
-
资助金额:$19.29万
-
财政年份:--
-
负责人:Justin A. Bishop
-
依托单位:
海外基金